Respiratory Syncytial Virus–Related Hospitalizations Among Infants Receiving Nirsevimab

This test-negative case-control study found that administration of nirsevimab to infants had high estimated effectiveness in preventing RSV disease severity that requires hospital-based care. The results suggest that nirsevimab has the potential to reduce the burden of RSV.

Corresponding Author: Sarah A. Buchan, PhD, Public Health Ontario, 661 University Ave, 17th Floor, Toronto, Ontario M5G 1M1, Canada (sarah.buchan@oahpp.ca); Stephen B. Freedman, MDCM, MSc, Pediatrics, University of Calgary, 28 Oki Dr NW, C4-634, Calgary, Alberta T3B 6A8, Canada (stephen.freedman@albertahealthservices.ca).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.